RT Generic
T1 The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
A1 El Bairi, Khalid
A1 Haynes, Harry R.
A1 Blackley, Elizabeth
A1 Fineberg, Susan
A1 Shear, Jeffrey
A1 Turner, Sophia
A1 de Freitas, Juliana Ribeiro
A1 Sur, Daniel
A1 Amendola, Luis Claudio
A1 Gharib, Masoumeh
A1 Kallala, Amine
A1 Arun, Indu
A1 Azmoudeh-Ardalan, Farid
A1 Fujimoto, Luciana
A1 Sua, Luz F.
A1 Liu, Shi-Wei
A1 Lien, Huang-Chun
A1 Kirtani, Pawan
A1 Balancin, Marcelo
A1 El Attar, Hicham
A1 Guleria, Prerna
A1 Yang, Wenxian
A1 Shash, Emad
A1 Chen, I-Chun
A1 Bautista, Veronica
A1 Do Prado Moura, Jose Fernando
A1 Rapoport, Bernardo L.
A1 Castaneda, Carlos
A1 Spengler, Eunice
A1 Acosta-Haab, Gabriela
A1 Frahm, Isabel
A1 Sanchez, Joselyn
A1 Castillo, Miluska
A1 Bouchmaa, Najat
A1 Zin, Reena R. Md
A1 Shui, Ruohong
A1 Onyuma, Timothy
A1 Yang, Wentao
A1 Husain, Zaheed
A1 Willard-Gallo, Karen
A1 Coosemans, An
A1 Perez, Edith A.
A1 Provenzano, Elena
A1 Ericsson, Paula Gonzalez
A1 Richardet, Eduardo
A1 Mehrotra, Ravi
A1 Sarancone, Sandra
A1 Ehinger, Anna
A1 Rimm, David L.
A1 Bartlett, John M. S.
A1 Viale, Giuseppe
A1 Denkert, Carsten
A1 Hida, Akira I.
A1 Sotiriou, Christos
A1 Loibl, Sibylle
A1 Hewitt, Stephen M.
A1 Badve, Sunil
A1 Symmans, William Fraser
A1 Kim, Rim S.
A1 Pruneri, Giancarlo
A1 Goel, Shom
A1 Francis, Prudence A.
A1 Inurrigarro, Gloria
A1 Yamaguchi, Rin
A1 Garcia-Rivello, Hernan
A1 Horlings, Hugo
A1 Afqir, Said
A1 Salgado, Roberto
A1 Adams, Sylvia
A1 Kok, Marleen
A1 Dieci, Maria Vittoria
A1 Michiels, Stefan
A1 Demaria, Sandra
A1 Loi, Sherene
A1 Int Immuno-Oncology Biomarker, 
K1 Tumor-infiltrating lymphocytes
K1 Neoadjuvant chemotherapy
K1 Prognostic-significance
K1 Predictive-value
K1 Free survival
K1 Trastuzumab
K1 Subtypes
K1 Microenvironment
K1 Identification
K1 Association
AB The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
PB Nature portfolio
YR 2021
FD 2021-12-01
LK https://hdl.handle.net/10668/26037
UL https://hdl.handle.net/10668/26037
LA en
DS RISalud
RD Apr 17, 2025